Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab alone versus bevacizumab + triamcinolone for diabetic macular edema
IRCT20211130053229N1Phase 2Completed
- Sponsor
- Kerman University of Medical Sciences
- Start
- Mar 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in diabetic macular edema (DME) comparing Intravitreal bevacizumab with Intravitreal bevacizumab + triamcinolone acetonide (2 arms). Primary endpoint: Change in best-corrected visual acuity. Started Mar 2023; status: completed.
02
Drugs
bevacizumabtriamcinolone acetonide
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on IRCT20211130053229N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211130053229N1.